112 related articles for article (PubMed ID: 22330940)
21. Association between bone turnover rate and bone microarchitecture in men: the STRAMBO study.
Chaitou A; Boutroy S; Vilayphiou N; Munoz F; Delmas PD; Chapurlat R; Szulc P
J Bone Miner Res; 2010 Nov; 25(11):2313-23. PubMed ID: 20499368
[TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
Cosman F; Borges JL; Curiel MD
Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
[TBL] [Abstract][Full Text] [Related]
23. [Biochemical markers of bone turnover : clinical usefulness in osteoporosis].
Garnero P; Delmas PD
Ann Biol Clin (Paris); 1999; 57(2):137-48. PubMed ID: 10210740
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of bone turnover markers in monitoring the withdrawal of treatment with oral bisphosphonates in postmenopausal osteoporosis.
Naylor KE; McCloskey EV; Jacques RM; Peel NFA; Paggiosi MA; Gossiel F; Walsh JS; Eastell R
Osteoporos Int; 2019 Apr; 30(4):917-922. PubMed ID: 30613868
[TBL] [Abstract][Full Text] [Related]
25. Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis.
Eastell R; Reid DM; Vukicevic S; Ensrud KE; LaCroix AZ; Thompson JR; Thompson DD; Cummings SR
Bone; 2012 May; 50(5):1135-40. PubMed ID: 22348983
[TBL] [Abstract][Full Text] [Related]
26. A rational approach to evidence gaps in the management of osteoporosis.
Rosen CJ; Brown SA
Am J Med; 2005 Nov; 118(11):1183-9. PubMed ID: 16271898
[TBL] [Abstract][Full Text] [Related]
27. Use of biochemical markers of bone turnover in the management of postmenopausal osteoporosis.
Camacho PM; Lopez NA
Clin Chem Lab Med; 2008; 46(10):1345-57. PubMed ID: 18844486
[TBL] [Abstract][Full Text] [Related]
28. Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness?
Chapurlat RD; Cummings SR
Osteoporos Int; 2002 Sep; 13(9):738-44. PubMed ID: 12195538
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review.
Funck-Brentano T; Biver E; Chopin F; Bouvard B; Coiffier G; Souberbielle JC; Garnero P; Roux C
Semin Arthritis Rheum; 2011 Oct; 41(2):157-69. PubMed ID: 21507464
[TBL] [Abstract][Full Text] [Related]
30. Bone markers and osteoporosis therapy.
Bandeira F; Costa AG; Soares Filho MA; Pimentel L; Lima L; Bilezikian JP
Arq Bras Endocrinol Metabol; 2014 Jul; 58(5):504-13. PubMed ID: 25166041
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of bone turnover markers does not improve persistence with ibandronate treatment.
Roux C; Giraudeau B; Rouanet S; Dubourg G; Perrodeau E; Ravaud P
Joint Bone Spine; 2012 Jul; 79(4):389-92. PubMed ID: 21703900
[TBL] [Abstract][Full Text] [Related]
32. Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.
Bonjour JP; Kohrt W; Levasseur R; Warren M; Whiting S; Kraenzlin M
Nutr Res Rev; 2014 Dec; 27(2):252-67. PubMed ID: 25394580
[TBL] [Abstract][Full Text] [Related]
33. Prognostic interest of bone turnover markers in the management of postmenopausal osteoporosis.
Chopin F; Biver E; Funck-Brentano T; Bouvard B; Coiffier G; Garnero P; Thomas T
Joint Bone Spine; 2012 Jan; 79(1):26-31. PubMed ID: 21723772
[TBL] [Abstract][Full Text] [Related]
34. [The role of bone metabolic markers in qualification for treatment of osteoporosis. Results of POMOST study].
Przedlacki J; Bartoszewicz Z; Ksiezopolska-Orłowska K; Kondracka A; Grodzki A; Bartuszek T; Bartuszek D; Swirski A; Loth E; Musiał J; Luczak E; Teter P; Lasiewicki A; Walkiewicz A; Drozdowska-Rusinowicz I
Endokrynol Pol; 2009; 60(1):25-32. PubMed ID: 19224502
[TBL] [Abstract][Full Text] [Related]
35. Biochemical bone turnover markers in hormonal disorders in adults: a narrative review.
Szulc P
J Endocrinol Invest; 2020 Oct; 43(10):1409-1427. PubMed ID: 32335857
[TBL] [Abstract][Full Text] [Related]
36. Biochemical assessment of bone turnover and bone fragility in men.
Szulc P; Kaufman JM; Delmas PD
Osteoporos Int; 2007 Nov; 18(11):1451-61. PubMed ID: 17566813
[TBL] [Abstract][Full Text] [Related]
37. Real-world bone turnover marker use: impact on treatment decisions and fracture.
Lane NE; Saag K; O'Neill TJ; Manion M; Shah R; Klause U; Eastell R
Osteoporos Int; 2021 May; 32(5):831-840. PubMed ID: 33236195
[TBL] [Abstract][Full Text] [Related]
38. [Evaluation of the efficacy and tolerance of ibandronic acid in patients with osteoarthrosis in the knee joints concurrent with osteoporosis: a pilot study].
Alekseeva LI; Zaitseva EM; Sharapova EP; Taskina EA; Smirnov AV; Demin NV; Aleksandrova EN
Ter Arkh; 2013; 85(5):30-6. PubMed ID: 23819336
[TBL] [Abstract][Full Text] [Related]
39. Clinical application of biochemical markers of bone turnover.
Seibel MJ
Arq Bras Endocrinol Metabol; 2006 Aug; 50(4):603-20. PubMed ID: 17117286
[TBL] [Abstract][Full Text] [Related]
40. Biochemical bone turnover markers and osteoporosis in older men: where are we?
Szulc P
J Osteoporos; 2011; 2011():704015. PubMed ID: 22220284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
